直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Favorable Federal Circuit ruling confirms the existence of a separate written description requirement

Ariad Pharmaceutical

Eli Lilly and Company

The U.S. Court of Appeals for the Federal Circuit, in an en banc opinion, confirmed the existence of a separate written description requirement that ensures that inventors have actually invented and described the subject matter claimed in their patents. The decision reversed a jury verdict against Finnegan client Eli Lilly and Company. Lilly had previously been found liable for infringing Ariad’s ’516 patent, and the jury had awarded Ariad a multi-million dollar verdict. The en banc opinion held that the asserted claims of the ’516 patent failed to satisfy the written description requirement of section 112 and were thus invalid.

Ariad Pharmaceutical v. Eli Lilly and Company, 1:02-cv-11280, D. Mass., Judge Zobel

Eli Lilly and Company v. Ariad Pharmaceutical, 08-1248, Fed. Cir., Judges Bryson, Dyk, Gajarsa, Linn, Lourie, Mayer, Michel, Moore, Newman, Prost, Rader

Related Professionals

Laura P. Masurovsky
Partner
Washington, DC
+1 202 408 4043
Email
Jennifer H. Roscetti
Partner
Washington, DC
+1 202 408 4150
Email

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

Federal Circuit win for Eli Lilly’s Xigris®, a recombinant form of human Activated Protein

Eli Lilly and Company

DuPont prevails on a written description defense to patent infringement at the Federal Circuit

DuPont Nutrition Biosciences APS

Federal Circuit confirms Patent Trial and Appeal Board wins for FedEx

FedEx Corp.

Federal Circuit reverses district court ruling of invalidity and upholds rulings on other grounds in favor of Finnegan client Eli Lilly and Co.

Eli Lilly and Company

Federal Circuit, district court, and arbitration victories protect Cumberland Pharmaceuticals’ flagship product, Acetadote®

Cumberland Pharmaceuticals

Federal Circuit confirms last IV patent at issue in E.D. Tex. Trial invalid

FedEx Corp.

Federal Circuit vacates IPR rulings in two appeals in favor of Finnegan client PPC Broadband

PPC Broadband

Federal Circuit affirms $6.5 million damages award for Finnegan client Telcordia Technologies from Cisco Systems

Telcordia Technologies

Federal Circuit rules Rambus semiconductor memory patent not anticipated

Rambus Inc.

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP